Skip to main content

Victrelis FDA Approval History

FDA Approved: Yes (Discontinued) (First approved May 13, 2011)
Brand name: Victrelis
Generic name: boceprevir
Company: Merck
Treatment for: Hepatitis C

Marketing Status: Discontinued

Victrelis (boceprevir) is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C.

Development timeline for Victrelis

DateArticle
May 14, 2011Approval FDA Approves Merck's Victrelis (boceprevir), First-in-Class Oral Hepatitis C Virus (HCV) Protease Inhibitor
Apr 28, 2011Victrelis (boceprevir) Unanimously Recommended for Approval By FDA Advisory Committee for Treatment of Chronic HCV Genotype 1 Infection
Jan  6, 2011Boceprevir, Merck's Investigational Oral Hepatitis C Protease Inhibitor, Receives FDA Priority Review and EMA Accelerated Assessment

See also

Victrelis (boceprevir) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer